Search This Blog

De Omnibus Dubitandum - Lux Veritas

Thursday, September 23, 2021

Gilead Study Shows Remdesivir Reduced Risk of Hospitalization When Given to COVID-19 Patients Early

By Zachary Stieber September 22, 20211

The antiviral remdesivir treatment reduced the risk of hospitalization among COVID-19 patients when administered soon after they were diagnosed, according to a new study from Gilead Sciences, which developed remdesivir.

Researchers found that remdesivir cut the risk of hospitalization by 87 percent compared to a placebo that half of the study participants received.

A total of 562 patients, all deemed at high-risk from COVID-19, were enrolled in the trial.

The Phase 3 study was a randomized, double-blind trial, but trial enrollment stopped in April because the company struggled to find enough participants. It continued to follow those who had enrolled, half of whom were given a placebo...........To Read More...

No comments:

Post a Comment